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dual-lumen venovenous extracorporeal membrane oxygenationAlexis E. Shafii, MD, Chase R. Brown, BS, Sudish C. Murthy, MD, PhD, and David P. Mason, MD,
Cleveland, OhioVenovenous extracorporealmembrane oxygenation (ECMO)
has emerged as an important intervention for patients
with acute respiratory failure, as well as as a bridge to lung
transplantation for end-stage lung disease.1,2 A recently
introduced bicaval, dual-lumen cannula appears to be a prom-
ising technologic advancement for venovenous ECMO sup-
port. Introduced percutaneously through the right internal
jugular or left subclavian vein, the Avalon Elite cannula (Av-
alon Laboratories, Rancho Dominguez, Calif) selectively
drains venous blood from the inferior and superior venae
cavae and infuses oxygenated blood directly into the right
atrium. Advantages of this cannula include a single insertion
and upper body placement, which can allow ambulation to
maintain patient conditioning.3Although the cannula is avail-
able inmultiple sizes (23-31F), clinical experience has shown
that larger cannula sizes are required to generate adequate
flow for respiratory support in adults (>4.0 L/min). Larger
cannulas used for extended durations, however, probably pre-
dispose the patient toward upper-extremity deep venous
thrombosis (DVT). We evaluated the incidence and subse-
quent clinical implications of upper extremity DVT in
patients who were supported with venovenous ECMO by
means of the Avalon dual-lumen cannula.MATERIALS AND METHODS
Between July 2009 and February 2012, we identified, from an institu-
tional review board–approved ECMO database, 10 patients who were
placed on venovenous ECMO with the Avalon dual-lumen cannula.
ECMO was initiated as a bridge to lung transplantation in 9 cases and
for adult respiratory distress syndrome in 1 case. Cannula placements
were all performed in the operating room under fluoroscopic and echocar-
diographic guidance. The right internal jugular vein was cannulated in 4
patients, and the left subclavian vein was used in 6 patients (Table 1). Sys-
tem components included a Quadrox D oxygenator with a Jostra RotaFlow
centrifugal pump and heparin-bonded Bioline tubing (Maquet Inc, Wayne,
NJ). Systemic anticoagulation was initiated with an intravenous heparin
bolus and infusion at the time of ECMO insertion and titrated for a goal par-
tial thromboplastin time of 45 to 65 seconds. ECMO separations were per-
formed through a limited cutdown incision, and hemostasis of theFrom the Department of Thoracic and Cardiovascular Surgery, Heart and Vascular In-
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the overlying soft tissue. All patients underwent upper-extremity surveil-
lance duplex ultrasonography.
RESULTS
Eight patients (80%) had acute upper-extremity DVT
while supported through the Avalon cannula. Median time
of ECMO support was 15 days (range, 3-40 days). DVT lo-
calization appeared to be related to the anatomic side of can-
nulation. Ipsilateral arm swelling or thrombophlebitis was
observed in all 8 patients with ultrasonographically con-
firmed upper-extremity DVTs. Five patients were managed
with systemic anticoagulation with heparin (or warfarin
after decannulation), whereas 3 patients did not receive anti-
coagulation because of relative contraindications (2 because
of postoperative or posttransplant coagulopathy and 1 be-
cause of gastrointestinal bleeding). Complete or partial res-
olution of clot was noted in all patients (6 complete and
2 partial) at a median of 23 days (range, 10-59 days) from
initial detection (Table 1). During this follow-up period,
no clinically apparent pulmonary embolisms occurred.
Two patients underwent contrast-enhanced computed tomo-
graphic scans after DVT detection; both were without
evidence of subclinical pulmonary embolism.
DISCUSSION
Upper-extremity DVTs have largely been regarded as
benign and self-limited, with low risk of pulmonary embo-
lism. A large series of upper-extremity DVTs demonstrated
a low prevalence of pulmonary embolism (3%), as opposed
to a much higher prevalence (16%) with lower-extremity
DVTs.4 In the setting of venovenous ECMO to treat respi-
ratory failure, however, large, central, upper-extremity
DVTs may predispose toward thromboembolism formation
in already compromised patients. We have previously noted
a high prevalence of DVTs (22%) with peripheral ECMO in
patients supported after lung transplantation, although the
clinical courses of these DVTs (and their long-term se-
quelae) have not been well defined.5 In this report, we
have documented a remarkably high prevalence of acute
upper-extremity DVTs with the use of the Avalon cannula,
both ipsilateral and contralateral to the site of insertion. This
is presumably due to partial obstruction of upper-body ve-
nous return and alteration in flow dynamics induced by
the large cannula positioned in the superior vena cava. Al-
though DVT formation might perhaps have been reduced
by higher heparin dosages (partial thromboplastin time
60-80 seconds), such as is used with venoarterial ECMO,ery c October 2012
TABLE 1. Patient characteristics
Case Age (y) Sex
ECMO
duration (d)
Cannula
size (F)
Cannulation
site
DVT
location
DVT
resorption
DVT
treatment
1 28 F 18 31 Left subclavian L-axillary Complete Yes
2 53 F 40 27 Left subclavian Left internal jugular, right
subclavian, and right axillary
Partial No
3 61 F 3 31 Left subclavian Left internal jugular Complete Yes
4 55 F 12 31 Left subclavian Right internal jugular, right
subclavian, and right axillary
Partial No
5 59 M 3 31 Right internal jugular Right internal jugular Complete Yes
6 56 F 5 27 Right internal jugular Right internal jugular Complete No
7 48 F 15 27 Right internal jugular Right internal jugular Complete Yes
8 33 F 15 23 Right internal jugular Left brachial Complete Yes
9 51 M 19 31 Left subclavian No DVT NA NA
10 58 M 21 31 Left subclavian No DVT NA NA
DVT, Deep venous thrombosis; ECMO, extracorporeal membrane oxygenation; F, female; M, male; NA, not applicable.
Brief Research Reportwe have used a generally accepted anticoagulation regimen
for venovenous ECMO. Fortunately, no clinically evident
pulmonary embolisms occurred, perhaps attributable to
our aggressive DVT treatment strategy. Of note, 2 patients
left untreated because of risk factors for bleeding demon-
strated incomplete DVT resolution, highlighting the impor-
tance of anticoagulation and the need for continued duplex
surveillance.
In conclusion, the Avalon cannula is an important innova-
tion that demonstrates promise for venovenous ECMO in
respiratory support. Clinicians should, however, be aware
of the high risk of DVT associated with its use and remain
vigilant with respect to treatment and radiologic follow-up.The Journal of Thoracic and CaReferences
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